Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study

Detalhes bibliográficos
Autor(a) principal: Fenley, Juliana de C. [UNESP]
Data de Publicação: 2022
Outros Autores: de Barros, Patrícia P. [UNESP], Carmo, Paulo H. F. do [UNESP], Garcia, Maíra T. [UNESP], Rossoni, Rodnei D. [UNESP], Junqueira, Juliana C. [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3390/cimb44110364
http://hdl.handle.net/11449/249358
Resumo: Candida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental candidiasis. For this, clinical strains of C. albicans were subjected to in vitro and in vivo treatments with ATV or DRV. As a result, ATV and DRV exhibited antifungal activity against fungal cells at 512 μg/mL, reduced the viability and biomass of biofilms, and inhibited filamentation of C. albicans. In addition, these HIV-PIs downregulated the expression of SAP2 and BRC1 genes of C. albicans. In an in vivo study, prophylactic use of ATV and DRV prolonged the survival rate of Galleria mellonella larvae infected with C. albicans. Therefore, ATV and DRV showed activity against C. albicans by reducing cell growth, biofilm formation, filamentation, and expression of virulence genes. Furthermore, ATV and DRV decreased experimental candidiasis, suggesting the repurposing of HIV-PIs as antifungal treatments for C. albicans infections.
id UNSP_b0889d855de2256402f3cdbbec1f0474
oai_identifier_str oai:repositorio.unesp.br:11449/249358
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Studyatazanavir sulfateCandida albicansdarunavirHIVprotease inhibitorsvirulence factorsCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental candidiasis. For this, clinical strains of C. albicans were subjected to in vitro and in vivo treatments with ATV or DRV. As a result, ATV and DRV exhibited antifungal activity against fungal cells at 512 μg/mL, reduced the viability and biomass of biofilms, and inhibited filamentation of C. albicans. In addition, these HIV-PIs downregulated the expression of SAP2 and BRC1 genes of C. albicans. In an in vivo study, prophylactic use of ATV and DRV prolonged the survival rate of Galleria mellonella larvae infected with C. albicans. Therefore, ATV and DRV showed activity against C. albicans by reducing cell growth, biofilm formation, filamentation, and expression of virulence genes. Furthermore, ATV and DRV decreased experimental candidiasis, suggesting the repurposing of HIV-PIs as antifungal treatments for C. albicans infections.Department of Biosciences and Oral Diagnosis Institute of Science and Technology São Paulo State University (Unesp), São PauloMulticampi School of Medical Sciences Federal University of Rio Grande do Norte (UFRN), Rio Grande do NorteDepartment of Biosciences and Oral Diagnosis Institute of Science and Technology São Paulo State University (Unesp), São PauloUniversidade Estadual Paulista (UNESP)Federal University of Rio Grande do Norte (UFRN)Fenley, Juliana de C. [UNESP]de Barros, Patrícia P. [UNESP]Carmo, Paulo H. F. do [UNESP]Garcia, Maíra T. [UNESP]Rossoni, Rodnei D. [UNESP]Junqueira, Juliana C. [UNESP]2023-07-29T15:13:51Z2023-07-29T15:13:51Z2022-11-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article5379-5389http://dx.doi.org/10.3390/cimb44110364Current Issues in Molecular Biology, v. 44, n. 11, p. 5379-5389, 2022.1467-30451467-3037http://hdl.handle.net/11449/24935810.3390/cimb441103642-s2.0-85141619011Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengCurrent Issues in Molecular Biologyinfo:eu-repo/semantics/openAccess2023-07-29T15:13:51Zoai:repositorio.unesp.br:11449/249358Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T21:39:34.600034Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
title Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
spellingShingle Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
Fenley, Juliana de C. [UNESP]
atazanavir sulfate
Candida albicans
darunavir
HIV
protease inhibitors
virulence factors
title_short Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
title_full Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
title_fullStr Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
title_full_unstemmed Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
title_sort Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
author Fenley, Juliana de C. [UNESP]
author_facet Fenley, Juliana de C. [UNESP]
de Barros, Patrícia P. [UNESP]
Carmo, Paulo H. F. do [UNESP]
Garcia, Maíra T. [UNESP]
Rossoni, Rodnei D. [UNESP]
Junqueira, Juliana C. [UNESP]
author_role author
author2 de Barros, Patrícia P. [UNESP]
Carmo, Paulo H. F. do [UNESP]
Garcia, Maíra T. [UNESP]
Rossoni, Rodnei D. [UNESP]
Junqueira, Juliana C. [UNESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
Federal University of Rio Grande do Norte (UFRN)
dc.contributor.author.fl_str_mv Fenley, Juliana de C. [UNESP]
de Barros, Patrícia P. [UNESP]
Carmo, Paulo H. F. do [UNESP]
Garcia, Maíra T. [UNESP]
Rossoni, Rodnei D. [UNESP]
Junqueira, Juliana C. [UNESP]
dc.subject.por.fl_str_mv atazanavir sulfate
Candida albicans
darunavir
HIV
protease inhibitors
virulence factors
topic atazanavir sulfate
Candida albicans
darunavir
HIV
protease inhibitors
virulence factors
description Candida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental candidiasis. For this, clinical strains of C. albicans were subjected to in vitro and in vivo treatments with ATV or DRV. As a result, ATV and DRV exhibited antifungal activity against fungal cells at 512 μg/mL, reduced the viability and biomass of biofilms, and inhibited filamentation of C. albicans. In addition, these HIV-PIs downregulated the expression of SAP2 and BRC1 genes of C. albicans. In an in vivo study, prophylactic use of ATV and DRV prolonged the survival rate of Galleria mellonella larvae infected with C. albicans. Therefore, ATV and DRV showed activity against C. albicans by reducing cell growth, biofilm formation, filamentation, and expression of virulence genes. Furthermore, ATV and DRV decreased experimental candidiasis, suggesting the repurposing of HIV-PIs as antifungal treatments for C. albicans infections.
publishDate 2022
dc.date.none.fl_str_mv 2022-11-01
2023-07-29T15:13:51Z
2023-07-29T15:13:51Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3390/cimb44110364
Current Issues in Molecular Biology, v. 44, n. 11, p. 5379-5389, 2022.
1467-3045
1467-3037
http://hdl.handle.net/11449/249358
10.3390/cimb44110364
2-s2.0-85141619011
url http://dx.doi.org/10.3390/cimb44110364
http://hdl.handle.net/11449/249358
identifier_str_mv Current Issues in Molecular Biology, v. 44, n. 11, p. 5379-5389, 2022.
1467-3045
1467-3037
10.3390/cimb44110364
2-s2.0-85141619011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Current Issues in Molecular Biology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 5379-5389
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129345263239168